Myelodysplastic syndrome, or MDS is a rare blood disorder that often develops into acute myeloid leukaemia. Guideline recommendations can support treatment decisions for these patients, but some questions remain about best practice. In today’s episode, we’ve invited Dr Platzbecker, clinical director in the Hematology and Cellular Therapy department at the University Hospital Leipzig, Germany, to expand on the guidelines to help you further improve your capacity to support patients with MDS.
References
Wells, et al. 2016; 188(10): 751
Greenberg, et al. J Natl Compr Canc Netw. 2017 Jan;15(1):60-87. 
Fenaux, et al. Ann Oncol. 2014; 25 Suppl 3: iii57-69
Fenaux, et al. Ann Oncol. 2020;S0923-7534(20)43129-1
This independent educational activity is supported by an educational grant from Servier Pharmaceuticals LLC and Takeda. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Servier and Takeda have had no influence on the content of this education.